Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …

Background. Interstitial lung disease (ILD) is the most common complication of systemic
sclerosis (SSc) with treatment ineffective. Objective: The aim of this meta‐analysis was to …

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

Although interstitial lung disease accounts for the majority of deaths of patients with systemic
sclerosis, treatment options for this manifestation of the disease are limited. Few high …

This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients
with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational …

Background We conducted a double-blind, randomized, placebo-controlled trial to
determine the effects of oral cyclophosphamide on lung function and health-related …

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC) …

Objective Our objective was to determine if treatment with cyclophosphamide (CYC) and
mycophenolate mofetil (MMF) improves patient‐reported outcomes (PROs) among patients …